Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

China’s NHSA Opens NRDL to AI and Digital Health Innovation, Unveils Scenario‑Driven Reimbursement Reform

Fineline Cube Feb 6, 2026
Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Fineline Cube Feb 6, 2026
Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Fineline Cube Feb 6, 2026
Company Deals

Bio-Thera Solutions Inks Licensing Deal with World Medicine for BAT2206

Fineline Cube Mar 5, 2025

China-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with World Medicine, granting...

Company Deals

Hainan Poly Pharm’s US Partner Slate Run Pharmaceuticals Collaborates with Premier on Contrast Agents

Fineline Cube Mar 5, 2025

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) announced a significant partnership between its US...

Company Deals

Gensaic and Novo Nordisk Team Up to Develop Cardiometabolic Therapies

Fineline Cube Mar 5, 2025

US-based AI-powered biotech Gensaic, Inc. announced the signing of a licensing and discovery cooperation agreement...

Company

MSD China Reorganizes to Boost Mature Product Lines

Fineline Cube Mar 5, 2025

Anna Van Acker, Senior Vice-President of Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) and...

Company Drug

Suzhou Abogen’s RSV mRNA Vaccine IND Approved by China’s CDE

Fineline Cube Mar 5, 2025

China-based nucleic acid drug developer Suzhou Abogen Biosciences announced that the Investigational New Drug (IND)...

Policy / Regulatory

CDE Launches SPARK Project to Boost Pediatric Antitumor Drug R&D

Fineline Cube Mar 5, 2025

China’s Center for Drug Evaluation (CDE) has released a notification to solicit feedback on its...

Company Drug

BeiGene’s Tevimbra Receives FDA Approval for ESCC Treatment

Fineline Cube Mar 5, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a multinational oncology company planning to change...

Company

Organon’s 2024 Financial Report Shows Steady Growth in Women’s Health and Biosimilars

Fineline Cube Mar 4, 2025

Women’s health specialist Organon (NYSE: OGN) released its 2024 financial report, showing a 3% year-on-year...

Company Drug

AstraZeneca and Daiichi Sankyo’s Enhertu Shows Positive Results in Phase III Study

Fineline Cube Mar 4, 2025

Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced positive topline results from the...

Company

Boehringer Ingelheim Appeals CNIPA’s Invalidation of Jardiance Patents

Fineline Cube Mar 4, 2025

The Intellectual Property Court of the Supreme People’s Court of China issued a notice, holding...

Company Drug

Genentech’s TNKase Approved by FDA for Acute Ischemic Stroke Treatment

Fineline Cube Mar 4, 2025

Genentech, a subsidiary of Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY), announced that its thrombolytic...

Company Drug

Eisai’s Lecanemab Rejected by Australia’s TGA for Early Alzheimer’s Treatment

Fineline Cube Mar 4, 2025

Japan-based Eisai Co., Ltd (TYO: 4523) announced that the Therapeutic Goods Administration (TGA) of Australia...

Company Deals Medical Device

Boston Scientific to Acquire SoniVie, Boosting Hypertension Treatment Portfolio

Fineline Cube Mar 4, 2025

Boston Scientific Corporation (NYSE: BSX) is set to acquire SoniVie Ltd, an Israel-based medical device...

Company Drug

Fapon Biopharma’s FP008 Receives FDA Approval for Clinical Trials

Fineline Cube Mar 4, 2025

China-based Fapon Biopharma announced that it has received clinical trial approval from the US Food...

Company Deals

Kyorin Pharmaceutical Licenses KRP-M223 to Novartis for Global Development

Fineline Cube Mar 4, 2025

Japan-based Kyorin Pharmaceutical Co., Ltd. announced a licensing agreement with Novartis (NYSE: NVS), granting the...

Company Drug

GSK’s Depemokimab Accepted for FDA Review as Ultra-Long-Acting Biologic

Fineline Cube Mar 4, 2025

GSK plc (LON: GSK, NYSE: GSK) announced that the US Food and Drug Administration (FDA)...

Company Drug

Juvestar and Raziel Therapeutics Launch Phase III Study for RZL-012 in China

Fineline Cube Mar 4, 2025

Juvestar Biotech Co., Ltd., a subsidiary of China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:...

Company Medical Device

Waters and Kehua’s LC-MS Systems Gain NMPA Approval for IVD Use

Fineline Cube Mar 4, 2025

Two home-grown liquid chromatography with tandem mass spectrometry (LC-MS) systems, the ACQUITY UPLC I-Class PLUS...

Company Drug

Zai Lab’s Augtyro Receives TFDA Approval for ROS1-Positive NSCLC and NTRK Fusion Solid Tumors

Fineline Cube Mar 4, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that it has received marketing...

Company Deals

Shanghai BioScience Completes RMB 100M Financing Round Led by HUAGAI Capital

Fineline Cube Mar 4, 2025

China-based Shanghai BioScience Co., Ltd., a life sciences service platform, announced the completion of a...

Posts pagination

1 … 157 158 159 … 621

Recent updates

  • Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
  • Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
  • Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
  • Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
  • Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.